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(57) ABSTRACT 
Compounds of the class of 4-oxo-butenoic acid derivatives 
are disclosed along with the surprising use property of these 
compounds as a anti-tumor agents in humans against breast 
carcinoma, which include: 2-(N'-Fluoren-9-ylidene-
hydrazino )-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl 
ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3-( 4-
me thy 1-benzoy 1 )-5-oxo-2,5-dihydro- lH-pyrrole-2-
carboxylic acid methyl ester (lF-07), 4-(4-Methoxy-
phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid (3F-
10), 4-( 4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-
butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5, 
6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15), 
and 4,4-Dihydroxy-5-( 4-methyl-benzoyl)-2-phenyl-2,4-
dihydro-pyrazol-3-one (3F-16) as well as some novel 
derivatives of these compounds claimed (see Table 2). The 
invention also encompasses a class of the compounds with 
the novel property of anti-tumor activity against human 
breast cancer, which includes the following compounds 
4-( 4-Ethoxy-pheny 1)-2-(N'-fiuoren-9-ylidene-hydrazino )-2-
hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N'-[1-
( 4-Chloro-phenyl)-ethylidene ]-hydrazino }-4-oxo-4-phenyl-
but-2-enoic acid methyl ester (OF-20); 2-(N'-Fluoren-9-
ylidene-hydrazino )-4-oxo-4-phenyl-but-2-enoic acid methyl 
ester (lF-04); and 4-Chloro-4-( 4-ethoxy-phenyl)-2-
(fiuoren-9-ylidene-hydrazono)-but-3-enoic acid methyl 
ester (3F-19). 
3 Claims, 2 Drawing Sheets 
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1 
TREATMENT OF BREAST CANCER 
This application claims benefit of Ser. No. 60/296,823 
filed Jun. 8, 2001. 
FIELD OF THE INVENTION 
5 
This invention relates to novel 4-oxo-butenoic acid 
derivatives and to the use of these compounds and related 
compounds with novel biological activity in humans as 
therapeutic means for the prevention and treatment of the 10 
human breast cancer and claims the benefit of priority of 
U.S. Provisional Application Serial No. 60/296,823 filed 
Jun. 8, 2001. 
BACKGROUND OF THE INVENTION 15 
2 
derivatives of carboxylic acid (column 9, line 31) and 
pyrrolidine (column 7, line 24); 
Brown (U.S. Pat. No. 6,066,670) describes an anti-viral 
admixture containing crotonic acid for treating tumors 
(see Abstract); 
Harwell, et al (U.S. Pat. No. 5,580,896) discloses many 
4-oxo-2-butenoic acid derivatives (column 13, lines 
21-59; also in columns 15+, examples 25,26,32,34,40, 
43-46,77-79, 97,99,103,106,), which are useful for 
inhibiting colorectal cancer, i.e., colon cancer 
(Abstract); and, 
Giordani, et al (U.S. Pat. No. 5,580,890) discloses 4-oxo-
2-butenoic acid derivatives said to be useful for treat-
ment of AIDS (column 1, line 8 and column 2, line 61; 
and, 
Yonemeto, et al (U.S. Pat. No. 6,083,985) recites a 
number of anti-tumor or anti-AIDS agents that include 
butenoic acid derivatives. 
Cancer is a global killer of humans with breast cancer 
among the leaders of killing humans yearly. Breast cancer is 
the primary killer of women. One in eight American women 
will develop breast cancer in her lifetime. In 2001, an 
estimated 192,700 women in the U.S. will be diagnosed with 
invasive breast cancer and 42,600 with in situ (tumors 
contained in the milk ducts). An estimated 40,000 will die 
from the disease. 
The U.S. patent literature has many disclosures of 
20 butanoic acid derivatives including: 
An estimated 3 million women in the U.S. today are living 
with breast cancer of which 2 million have been diagnosed 25 
with the disease and I million have the disease but do not yet 
know it. 
The incidence of breast cancer in the U.S. has more than 
doubled in the past 30 years. In 1964, the lifetime risk was 
1 in 20. Today it's 1 in 8. Breast cancer is the most 30 
commonly diagnosed cancer in women in both America and 
worldwide. Breast cancer rates are the highest in industri-
alized countries. It is estimated that 1.2 million new diag-
noses and 500,000 deaths from breast cancer will occur 
worldwide this year. Further, it appears that breast cancer is 35 
the leading cause of death for American women of ages 25 
to 55 years. 
No vaccine or other universally successful method for the 
prevention or treatment of breast cancer is currently avail-
able. Management of the disease currently relies on a 40 
combination of early diagnosis (through routine breast 
screening procedures) and aggressive treatment, which may 
include one or more of a variety of treatments such as 
surgery, radiotherapy, chemotherapy and hormone therapy. 
The course of treatment for a particular breast cancer is often 45 
selected based on a variety of prognostic parameters, includ-
ing an analysis of specific tumor markers. {Porter-Jordan 
and Lippman, Breast Cancer 8:73-100 (1994)}. However, 
the use of established markers often leads to a result that is 
difficult to interpret, and the high mortality observed in 50 breast cancer patients indicates that improvements are 
needed in the treatment, diagnosis and prevention of the 
disease. 
Accordingly, there is a need for improved methods for 
chemotherapy for breast cancer. The present invention ful-
55 fills this need and further provides other related advantages. 
The U.S. patent literature has many disclosures of oxo-
butenoic ( crotonic) acid derivatives: 
Pamukci (U.S. Pat. No. 6,232,312) describes crotonic acid 
derivatives (column 22, lines 43-58) for the treatment 60 
of colonic polyps; 
Nicolai, et al (U.S. Pat. No. 6,180,651) discloses many 
anti-inflammatory and analgesic compounds, including 
adenocarcinoma (column 1, line 55), which includes 
heterocyclic alcohol-esters (column 11, lines 1-16) and 
butanoic acid derivatives (many Examples including 47 
through 162); 
Girard, et al (U.S. Pat. No. 5,308,852) discloses many 
compounds including butanoic acid derivatives (see 
Methods B and C of schemes II and III) which com-
pounds which are said to inhibit tumor metastasis 
(column 7, line 56 and column 8, line 4); and, 
Frechette (U.S. Pat. No. 5,696,117), Frechette(U.S. Pat. 
No. 5,854,242) and Frechette (U.S. Pat. No. 5,707,990) 
describe 148 benzoxazine and pyrido-oxazine hetero-
cyclics as anti-bacterial compounds. 
It appears from the foregoing that the derivatives of 
4-oxo-butanoic acid of interest are not disclosed and thus 
there is no report of their activity against human breast 
cancer. 
Consequently, there is a need for an anti-cancer drug for 
humans that mitigates the above mentioned disadvantages of 
current drug therapy and effectiveness against human breast 
cancer. 
SUMMARY OF THE INVENTION 
The first objective of the present invention is to provide a 
drug effective for treatment of human breast cancer. 
Another object of this invention is to provide novel 4-oxo-
butenoic acid derivatives. 
A further object of this invention is to provide 4-oxo-
butenoic acid derivatives with novel activity against human 
breast cancer. 
A preferred embodiment of the invention encompasses a 
class of compounds having the property of anti-tumor activ-
ity against human breast cancer comprising the novel struc-
tures of 4-oxo-butenoic derivatives and more specifically 
those derivatives: 2-(N'-Fluoren-9-ylidene-hydrazino )-5,5-
dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06); 1-(2, 
4-Dime thy 1-p heny 1)-2,4-dih ydroxy-3-( 4-me thy 1-benzo y 1)-
5-o xo-2,5-dih ydro- lH-pyrro le-2-carboxy lic acid methyl 
ester (lF-07); 4-( 4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-
hydrazono )-butyric acid (3F-10); 4-( 4-Chloro-phenyl)-2,4-
dioxo-3-(phenyl-hydrazono )-butyric acid ethyl ester (3F-
11); 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro-4-methoxy-
phenyl)-but-2-enoic acid (3F-15); and 4,4-Dihydroxy-5-(4-
Jones et al (U.S. Pat. No. 6,121,450) discloses crotonic 
acid derivatives (column 8, tine 34; column 78, line 24 
and at example 34 as steroid modifiers in treating breast 
cancer (column 1, lines 55-58); 
Kalden, et al (U.S. Pat. No. 5,334,612) discloses com-
pounds said to be useful for treating AIDS including 
65 methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-
16) as well as novel derivatives of these compounds (see 
Table 2). 
US 6,602,907 Bl 
3 
The use of the following compounds for humans as 
therapeutic means for the eradication of human breast cancer 
further encompasses the following: 4-( 4-Ethoxy-phenyl)-2-
(N'-fiuoren-9-y lidene-hydrazino )-2-hydroxy-4-oxo-butyric 
acid methyl ester (OF-13); 2-{N'-[1-( 4-Chloro-phenyl)- 5 
ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid 
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino )-
4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and 
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidene-
hydrazono )-but-3-enoic acid methyl ester (3F-19). 
10 
Further objects and advantages of this invention will be 
apparent from the following detailed description of presently 
preferred embodiments, which are illustrated structurally in 
the accompanying drawings. 
BRIEF DESCRIPTION OF THE FIGURES. 
FIG. 1 illustrates structurally a chemical compound des-
ignated as OF-06. 
FIG. 2 illustrates structurally a chemical compound des-
ignated as lF-07. 
FIG. 3 illustrates structurally a chemical compound des-
ignated as 3F-10 
FIG. 4 illustrates structurally a chemical compound des-
ignated as 3F-11 
15 
20 
FIG. 5 illustrates structurally a chemical compound des- 25 
ignated as 3F-15 
FIG. 6 illustrates structurally a chemical compound des-
ignated as 3F-16 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
30 
Before explaining the disclosed embodiments of the 
present invention in detail, it is to be understood that the 
invention is not limited in its application to the details of the 35 
particular arrangement shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
As earlier recited this application has been filed in order 
to disclose: new 4-oxo-butenoic acids that have been found 40 
to have high activity against human breast cancer and low 
toxicity in animals. 
4 
the compound designated as lF-07 is 1-(2,4-Dimethyl-
phenyl)-2,4-dihydroxy-3-( 4-methyl-benzoyl)-5-oxo-2, 
5-dihydro-lH-pyrrole-2-carboxylic acid methyl ester; 
the compound designated as 3F-10 is 4-(4-Methoxy-
phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid 
the compound designated as 3F-11 is 4-(4-Chloro-
phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid 
ethyl ester; 
the compound designated as 3F-15 is 2-Hydroxy-4-oxo-
4-(2,3,5,6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic 
acid and, 
the compound designated as 3F-16 is 4,4-Dihydroxy-5-
( 4-methyl-benzoy 1)-2-pheny 1-2,4-dihydro-pyrazol-3-
one. 
These compounds have very.high activity against human 
breast cancer and a very low toxicity as Lethal Dose 50 
(LD50) in animals. The percent activity and animal toxicity 
for each compound is as follows: 
OF-06 (100% against human breast carcmoma and 
LD50>3000 mg/kg); 
lF-07 (100% against human breast carcmoma and 
LD50>500 mg/kg); 
3F-10 (100% against human breast carcinoma and LD50 , 
<750 mg/kg); 
3F-11 (100% against human breast carcmoma and 
LD50>2000 mg/kg); 
3F-15 (100% against human breast carcmoma and 
LD50>200 mg/kg); and, 
3F-16 (100% against human breast carcmoma and 
LD5 >500 mg/kg) 
PREPARATION OF (OF-06). 
EXAMPLE 1 
The preparation of 2-(N'-Fluoren-9-ylidene-hydrazino )-5, 
5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06). A 
solution of 5.0 g (0.02 moles) of 2-hydroxy-5,5-dimethyl-
4-oxo-hex-2-enoic acid methyl ester (1) (synthesis was 
previously published by E. Royals. JAm.Chem.Soc., 1945, 
67, 1508) and 3.88 g (0.02 moles) of fiuoren-9-ylidene-
hydrazine (2) in 80 mL of absolute toluene was refluxed for 
3 hr 30 min with a Dean-Stark trap (control for the end of 
the reaction was carried by TLC). The solution was cooled 
and the precipitate was filtered and recrystallized from 
absolute benzene-hexane (1:1) to give 3.4 g (68% yield) of 
yellow crystals, mp 135-137° C. 
More specifically this application is for the novel anti-
tumor compounds OF-06, lF-07, 3F-10, 3F-11, 3F-15 and 
3F-16 which have been structurally shown in FIGS. 1-6, 45 
respectively, as well as novel derivatives of these com-
pounds claimed (see Table2) and the activity against human 
breast cancer of compounds OF-13, OF-20, lF-04, and 3F-19 
also as shown in Table 1 along with anti-tumor activity and 
toxicity. 
To facilitate a full understanding of the invention: 
50 Solubility: highly soluble in DMSO, DMFA, dichloroethane, acetonitrile, slightly soluble in ethanol, 
tetrachloromethane, insoluble in hexane and water. the compound designated as OF-06 is 2-(N'-Fluoren-9-
y lidene-hydrazino )-5,5-dimethy1-4-oxo-hex-2-enoic 
acid methyl ester; 
CH3 
I 
The synthesis of OF-06 is an example of well known 
amination/dehydration reactions. 
CH3-C-CO-CH=C-COOCH3 + 
I I 
CH3 OH 
US 6,602,907 Bl 
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-continued 
CH3 
I 
CH3 
I 
CH3-C-CO-CH=C-COOCH3 
I I 
CH3-C-CO-CH2-C-COOCH3 
I II 
CH3 NH 
I 
~ 
lJLJJ 
A 
OF-06 
PREPARATION OF (lF-07) 
EXAMPLE 2 
The preparation of 1-(2,4-Dimethyl-phenyl)-2,4-
dihydroxy-3-( 4-methy 1-benzoy 1)-5-oxo-2,5-dihydro-lH-
pyrrole-2-carboxylic acid methyl ester (lF-07). To a solution 
of 1.65 g (0.0051 moles) of 2-(2,4-diinethyl-phenylamino)-
4-oxo-4-p-tolyl-but-2-enoic acid methyl ester (1) in 20 mL 
of anhydrous chloroform was added 0.68 g (0.0054 moles) 
oxalyl chloride. After refluxing for 30 min, 10 mL of 
anhydrous hexane was added and 15 ml of solvent was 
distilled out. The remainder of the solvent was evaporated 
CH3 N 
I 
15 
~ 
V-----1J 
B 
phenyl)-4-oxo-but-2-enoic acid in 300 ml of dioxane small 
potions of an aqueous solution prepared from 0.075 moles of 
aniline, 0.92 moles of sodium nitrate and 19 ml of concen-
trated HCl in 90 ml of water (DI) was added. During cooling 
20 11.4 g of sodium acetate was added and the reaction was 
kept at the r.t. for 24 hr. Then 2 L of water was added to the 
reaction mixture and the resulting precipitate was filtrated 
and recrystallized from 1: 1 mixture of dimethyl chloride/ 
ethyl acetate to give 15.93 g of yellow crystals (60% yield) 
25 with m.p. of 176-177 (decamp). 
by keeping the flask open for 12 hr. The resulting precipitate 
was filtered and recrystallized from dichloroethane-
tetrachlorometane (1:2) to give 1.25 g (62%) of compound 
30 lF-7 in the form of white crystals, mp 133-135° C. 
(decamp.) 
Solubility: highly soluble in DMSO, DMFA, slightly 
soluble in chloroform, dichloroethane; insoluble in hexanes. 
H3Co-O-co-cH=1-cooH 
OH 
+ 
Solubility: highly soluble in DMSO, acetonitrile, slightly 
soluble in dichloroethane, benzene, insoluble in hexane 
tetrachloromethane and water. 
H3C~COOCH3 
0 NH n,c'¢ 
CH3 
1. (COC1)2,t 
2.H20 
35 
40 
3F-10 
45 PREPARATION OF (3F-11) 
EXAMPLE 4 
50 The preparation of 4-( 4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid ethyl ester (3F-11). A solu-
tion of 0.5 g (0.0016 moles) of 5-(4-Chloro-benzoyl)-2-
phenyl-2H-pyrazole-3,4-dione (1) (synthesis was previously 
published by Pimenova, E. V; Andreichikov, Yu. S. (1992) 
Zh. Org. Khim. 28, 376-89). in 2 mL of anhydrous ethanol 
was refluxed for 1 hr. The resulting solution was cooled and 
the precipitate was filtered to give 0.48 g (85% yield) of 
yellow crystals with m.p. of 141-142° C. (decamp). 
PREPARATION OF (3F-10) 
EXAMPLE 3 
lF-7 
The preparation of 4-( 4-Methoxy-phenyl)-2,4-dioxo-3- 65 
(phenyl-hydrazono)-butyric acid (3F-10). To a hot stirred 
solution of 0.075 moles of 2-Hydroxy-4-( 4-methoxy-
US 6,602,907 Bl 
7 
-continued 
N-NHC6Hs 
8 
by Pimenova, E. V; Andreichikov, Yu. S. (1992) Zh. Org. 
Khim. 28, 376-89), and 5 mL of water (DI) was kept at the 
rt until the solution became colorless and precipitate was 
formed. The precipitate was filtered and recrystallized from o--ohcooc,n, 
0 0 
5 dichloroethane-water (10:1) to give 0.45 g (85%) of yellow-
brown crystals, mp 134-135° C. 
3F-11 
PREPARATION OF (3F-15) 
EXAMPLE 6 
The preparation of 2-Hydroxy-4-oxo-4-(2,3,5,6-
tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15). A 15 
solution of sodium methoxide was prepared from 0.46 g (20 
mmol) of sodium and 30 mL of absolute methanol by 
addding small portions to a mixture of 6.35 g (10 mmol) of 
1-pentafiuorophenyl-ethanone 1 and 3.54 g (10 mmol) of 
dimethyl oxalate 2. After stirring the reaction for 24 hr at rt, 20 
50 mL of 25% aqueous solution of HCl was added. The 
resulting mixture was extracted with ether (240 mL), 
washed by solution of brine and dried over anhydrous 
Na2S04 . The solvent was removed in vacuum and 10 mL of 
saturated solution of NaOH in ethanol was added with 25 
stirring. After 1 hr the reaction mixture was diluted with 
water and acidified with H2S04 (10%) to obtain pH of 1-2. 
The resulting precipitate of 3F-15 was filtered and recrys-
tallized from toluene to give 1.73 g (81 % yield) in the form 
of white-yellow crystals, mp 155-156° C. (decamp.). 30 
C6Fs-CO-CH3 + (COOCH3)2 
2 
2)HC1 
3) NaOH/C2HsOH 
F F ~ 
3F-16 
Solubility: highly soluble in DMSO, dioxane, insoluble in 
water. 
PREPARATION OF (OF-13) 
EXAMPLE 8 
The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fiuoren-9-
ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl 
ester-(OF-13). A solution of 5.0 g (0.02 moles) of methyl 
4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and 
3.88 g (0.02 moles) of fiuorene-9-ylidene-hydrazine (2) in 
H3CO*j CO-CH=1-cooH 
OH 
F F 
3F-15 
40 80 mL of absolute benzene and absolute toluene (1:1) was 
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of 
the reaction was determined by TLC), cooled and the 
precipitate was filtered and recrystallized from benzene -
PREPARATION OF (3F-16) 
EXAMPLE 7 
The preparation of 4,4-Dihydroxy-5-( 4-methyl-benzoyl)-
2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16). A solution of 
0.5 g (0.0017 moles) of 5-( 4-Methyl-benzoyl)-2-phenyl-2H-
pyrazole-3,4-dione (1) (synthesis was previously published 
45 
diethyl ether - hexane mixture (1:3:2) to give 2.65 g (53% 
yield) of colorless crystals with mp 114-116° C. 
Solubility: highly soluble in DMSO, DMFA, 
dichloroethane, acetonitrile, insoluble in hexane. The com-
50 pound is not stable in solutions and decomposes quickly 
when the solution is heated or stored for a long time with the 
formation of OF-12. 
+ 
US 6,602,907 Bl 
9 10 
-continued 
OH ~COOCH3 
C2HsO~ , __ _ 
0 NH 
~ OF-13~ 
-
-
It is seen from the above that (OF-13) is an intermediate 
product during the synthesis of (OF-12). 
PREPARATION OF (3F-19) 
EXAMPLE 9 
The preparation of 4 Chloro 4 ( 4 ethoxy phenyl) 2 (fiuoren 
9 ylidene hydrazono) but 3 enoic acid methyl ester (3f-19) 
to the solution of 10 g (0.0026 moles of 4 (4 Ethoxy phenyl) 
2 (N'fiuoren 9 yliden hydrazine) 4-oxo-but-2-enoic acide 
methyl ester (OF-12) (synthesis was previously published by 
30 Konyukhova, N. A.; Krasnykh, 0. P.; Aliev, Z. G.; 
Maslivets, A. N. Cehmistry of Hetorcyclic Compounds (New 
York, N.Y., United States) (Translation of Khimiya 
Geterotsiklicheskikh Soedineii) (2001), 37(6), 779-780) in 
5 mL of anhydrous benzene 0.3935 g (0.0031 moles) oxalyl 
35 chloride was added. The reaction mixture was refluxed for 1 
hour 40 min, cooled, precipitate was filtered and recrystal-
lized from absolute benzene to give 0.62 g (54%) of yellow 
crystals, m.p. 163-163 (decom). 
OF-12 
(COCl)2i 
C2H5o--O--co-cH2-IT-coocH3 
_......N 
N 
~ 
V----JJ 
HsC20--0--1=cH-IT-coocH3 
Cl _......N 
'"° ~ 
# 
OF-13 
OF-20 
lF-04 
US 6,602,907 Bl 
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TABLE 1 
Some Compounds of the Invention 
Structure 
OH C2HsO~COOMe 
0 NH....,_ 
N 
~ 
lJ-----Jl) 
0 /NH 
N ffrn, 
Cl # 
0 /NH 
ex)) 
Name 
4-( 4-Ethoxy-phenyl)-2-
(N' -fluoren-9-y lidene-
h ydrazino )-2-hydroxy-4-
oxo-butyric acid methyl 
ester 
2-{N'-[1-( 4-Chloro-
phenyl)-ethylidene ]-
hydrazino }-4-oxo-4-
phenyl-but-2-enoic acid 
methyl ester 
2-(N'-Fluoren-9-ylidene-
hydrazino )-4-oxo-4-
phenyl-but-2-enoic acid 
methyl ester 
4-Chloro-4-( 4-ethoxy-
phenyl)-2-(fluoren-9-
ylidene-hydrazono )-but-
3-enoic acid methyl ester 
12 
Activity LD50, 
(ATCC HIB123) 
100% 
83% 
93% 
100% 
mg/kg Reference 
>1500 Miles et. al. UCF-303A 
>250 Miles et. al. UCF-311C 
>1000 Andrejchikov, Yurij S.; 
Maslivets, Andrej N.; 
Krasnykh, Olga P.; 
Aleksandrova, Galina A.; 
Vozhakova, Alla V Russ. 
(1993), CODEN: RUXXE7 
RU 2003655 Cl 19931130 
Application: RU 91-
5013322 19910704. 
>200 Konyukhova, N. A.; 
Krasnykh, 0. P.; Aliev, 
Z. G.; Maslivets, A. N. 
Chemistry of Heterocyclic 
Compounds (New York, 
NY, United States) 
(Translation of Khimi ya 
Getero-tsiklicheskikh 
Soedinenii) (2001), 37(6), 
779-780. 
# Structure 
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TABLE 2 
Derivatives of 3F-10 having potential anti-tumor activity 
Name 
3-[ ( 4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester 
3-[ ( 4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-p-tolyl-butyric acid methyl ester 
2,4-Dioxo-4-p-tolyl-3-(p-tolyl-hydrazono)-butyric acid methyl ester 
3-[ ( 4-Chloro-phenyl)-hydrazono ]-4-( 4-methoxy-phenyl)-2,4-dioxo-butyric acid methyl ester 
0 
¢ 
Cl 
# Structure 
5 
Cl 
Cl 
7 
Cl 
8 
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TABLE 2-continued 
Derivatives of 3F-10 having potential anti-tumor activity 
Name 
4-( 4-Chloro-phenyl)-2,4-dioxo-3-(p-tolyl-hydrazono )-butyric acid methyl ester 
OCH3 4-(4-Chloro-phenyl)-3-[(4-methoxy-phenyl)-hydrazono ]-2,4-dioxo-butyric acid methyl ester 
I 
N 
'NH 
0 
0 
6 
4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid ethyl ester 
2,4-Dioxo-3-(phenyl-hydrazono)-4-p-tolyl-butyric acid ethyl ester 
# Structure 
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TABLE 2-continued 
Derivatives of 3F-10 having potential anti-tumor activity 
Name 
2,4-Dioxo-4-phenyl-3-(phenyl-hydrazono)-butyric acid methyl ester 
2,4-Dioxo-3-(phenyl-hydrazono)-4-p-tolyl-butyric acid methyl ester 
4-(4-Bromo-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid methyl ester 
4-(4-Methoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester 
0 
6 
I 
N 
'NH 
OCH3 4-(4-Ethoxy-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester 
0 
6 
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TABLE 2-continued 
Derivatives of 3F-10 having potential anti-tumor activity 
# Structure Name 
14 4-(4-Fluoro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester 
F 
I 
N 
'NH 
0 
6 
15 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono)-butyric acid methyl ester 
Cl 
16 3-[ ( 4-Methoxy-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester 
I 
N 
'NH 
0 
¢ 
OCH3 
17 3-[ ( 4-Chloro-phenyl)-hydrazono ]-2,4-dioxo-4-phenyl-butyric acid methyl ester 
I 
0 
N'-. 
NH ¢ 
Cl 
CYTOTOXICITY ASSAY 
The activity in human breast cancer of the novel com-
pounds (as earlier reported) was realized by the following 
procedure which determines the inhibitory effect of test 
samples on the growth of human breast cancer cells. 
(ATCC HTB123) The HTB123 cells are grown in RPMI 
1640 media +10% Fetal bovine serum +4.Sg/L glucose +10 
mM HEPES + 1.0 mM sodium pyruvate + 1 % Antibiotic/ 
60 Antimycotic for approximately 48 hours at 37° C./5% C02 
in the presence of the test compound. 
Growth/Non-Growth of the cells (e.g., cell density) is 
determined using Promega's MTS/PMS assay system. MTS 
(3-( 4,5-dime thylthiazo l-2-yl)-5-(3-
65 carboxymethoxypheny 1)-2-( 4-sulfopheny l)-2H-tetrazolium, 
inner salt) is an aqueous compound that is reduced to soluble 
formazan by the presence of NADH formed by dehydroge-
US 6,602,907 Bl 
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nases present within the HTB123 cells. The absorbance of 
the formazan can be measured at 490 nm and is directly 
proportional to the number of living cells present in the 
culture. PMS (Phenazine Methosulfate) is added an electron 
coupling reagent and greatly increases the rate of reduction. 5 
To facilitate a full understanding of the procedure the 
following definitions are offered: 
Test wells-wells containing test sample and Diluted 
HTB123 cells 
22 
USE OF THE INVENTION FOR TREATMENT 
OF HUMAN BREAST CANCER 
Test values-absorbance of test wells 
Blank wells-wells containing test sample and HTB 123 
media (HHTB2-01S); used to obtain background 
absorbance due to test sample 
Blank values-absorbance of blank wells 
The compounds of the invention, i.e. 4-oxo-butenoic 
acids derivatives and more specifically those novel deriva-
tives: 2-(N'-Fluoren-9-ylidene-hydrazino )-5,5-dimethyl-4-
oxo-hex-2-enoic acid methyl ester (OF-06); 1-(2,4-
Dimethy 1-pheny 1)-2,4-dihydroxy-3-( 4-meth y 1-benzoy 1)-5-
oxo-2,5-dihydro- lH-pyrrole-2-carboxy lic acid methyl ester 
(lF-07); 4-( 4-Methoxy-pheny 1)-2,4-dioxo-3-(phenyl-
10 hydrazono )-butyric acid (3F-10); 4-( 4-Chloro-phenyl)-2,4-
dioxo-3-(phenyl-hydrazono )-butyric acid ethyl ester (3F-
11); 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro-4-methoxy-
phenyl)-but-2-enoic acid (3F-15) and, 4,4-Dihydroxy-5-(4-
methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F-
15 
Negative Control-maximal cell growth; results of test 
samples will be expressed as a percent of the Negative 
Control 
16), as well as all novel derivatives of these compounds 
Positive Control-known inhibitor of HTB 123 cells; 
used to validate assay system 
Matrix-solvent that the samples are prepared/diluted in 
Assay samples of similar origin and matrix (e.g., metha-
nol extraction, methylene chloride extraction, water soluble 
samples, etc.) together on the same plate in order to reduce 
the number of steps performed per plate. 
claimed (see Table2), and the additional compounds of Table 
1 with activity against human breast cancer which include 
the following compounds 4-( 4-Ethoxy-phenyl)-2-(N'-
fiuoren-9-ylidene-hydrazino )-2-hydroxy-4-oxo-butyric acid 
20 
methyl ester (OF-13); 2-{N'-[1-(4-Chloro-phenyl)-
ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid 
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)-
4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and 
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidene-
25 hydrazono)-but-3-enoic acid methyl ester (3F-19). 
Blank values will be determined for each sample to 
account for any color contribution due to the sample itself. 
These blank wells must contain the same amount of sample 
plus HTB 123 media (no cells). After completion of MTS/ 
PMS reaction blank values will be subtracted from the test 30 
value to obtain a net absorbance that will be used to calculate 
cell density. 
All results are based upon a comparison to the Negative 
Control value of the plate. The Negative Control must 
contain the same amount of matrix (e.g., solvent) to offset 35 
any destructive effect the matrix may have on the growth of 
the HTB123 cells (allows for baseline values to be set). 
For most samples, a HTB123 cell growth (diluted two to 
four-fold, depending upon the appearance of the inoculum*) 
of approximately 48 hours followed by and incubation of 3 40 
hours with the MTS/PMS Reagent is optimal. 
*Due to the nature of the HTB123 cells it is very difficult 
to obtain accurate cell densities. Continuation of the 
HTB123 cell line typically consists of the dilution of mature 
cells at two or three-fold into fresh media and growth at 37° 45 
C./5% C02 for two to three days. 
In order to establish the accuracy of this assay a Positive 
Control consisting of 50 µM Methotrexate should not 
decrease the net absorbance to less than 90% of the Negative 
Control (HTB123 cells are somewhat resistant to 50 
methotrexate) is utilized. 
All the compounds are unique in the in vitro treatment of 
humans and can be used as therapeutic means for the 
eradication of tumors from the human breast in a pharma-
ceutical composition comprising a non-toxic effective 
amount of the referenced compound or a tautomeric form 
thereof or a pharmaceutically acceptable salt thereof or 
pharmaceutically acceptable solvate thereof, and a pharma-
ceutically acceptable carrier thereof. 
For administration to man in the curative or prophylactic 
treatment of human breast cancer in vitro dosages of com-
pounds of the invention will generally be in the range of 
from 5 to 500 mg daily for an average adult patient (70 kg). 
Thus for a typical adult patient, individual tablets or capsules 
contain from 2-500 mg of active compound, in a suitable 
pharmaceutically acceptable vehicle or carrier, for adminis-
tration in single or multiple doses, once or several times per 
day. Dosages for intraveneous, buccal or sublingual admin-
istration will typically be within the range of from 5-1000 
mg per single dose as required. In practice the physician will 
determine the actual dosing regimen which will be most 
suitable for an individual patient and it will vary with the 
age, weight and response of the particular patient. The above 
dosages are exemplary of the average case but there can be 
individual instances in which higher or lower dosage ranges 
may be merited, and such are within the scope of this 
invention. 
ANIMAL TOXCITY BIOASSAY 
Acute toxicity was studied on white mice of both sexes 
with weight ranging between 18-26 grams under intraperi-
toneal injection of 2% solution of tested compound in starch 
(the compound was dissolved in starch slime and injected) 
The maximum human non-toxic one time administration 
dose for the compound(s) of the invention appears to range 
55 from 100 to 1500 mg. 
on the basis of 0.1 ml of solution per 10 g of the animal 
weight. Each dose was tested on the group of 6 animals that 
were observed during 14 days period. (This method was 60 
approved by the Pharmacology committee of Russian Min-
istry of Health and has been widely used since 1968.) 
Averaged lethal dose (LD50) of the compound was com-
puted using results of experiments on 5-7 groups of animals 
using method of Litchfield and Wilkinson. (Belenkii M. L. 65 
"Elements of quantative determination of the pharmacologi-
cal effect," Leningrad, 1963, 71 pages). 
For human use, the compounds of the invention can be 
administered alone or jointly, but will generally be admin-
istered in admixture with a pharmaceutical carrier selected 
with regard to the intended route of administration and 
standard pharmaceutical practice. For example, they may be 
administered orally, buccally or sublingually, in the form of 
tablets containing excipients such as starch or lactose, or in 
capasules or ovules either alone or in admixture with 
excipients, or in the form of elixirs or suspensions contain-
ing flavouring or colouring agents. The compounds may also 
be injected parenterally, for example intraveneously, 
intramuscularly, subcutaneously or intracoronarily. For 
US 6,602,907 Bl 
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parenteral administration, they are best used in the form of 
a sterile aqueous solution which may contain other 
substances, for example enough salts or glucose to make the 
solution isotonic with blood. 
24 
Taxol is perhaps best viewed as an exciting and valuable 
lead in cancer chemotherapy. Although Taxol has extended 
the life of many people, it is not a cure, and many patients 
develop resistance to it. Many tumor types show minimal or 
5 no response to Taxol, and there are solubility problems in 
drug delivery. 
The invention thus provides a method for the treatment of 
breast carcinoma in a human mammal which comprises 
administering an effective, non-toxic, amount of a hetero-
cyclic compound according to the invention or a tautomeric 
form thereof and/or a pharmaceutically acceptable salt 
thereof and/or a pharmaceutically acceptable solvate thereof 10 
to a breast carcinoma invaded human mammal in need 
thereof. 
ADVANTAGES OF THE INVENTION 
Accordingly, there is a need in the art for improved 
methods for therapy and diagnosis of breast cancer. The 
present invention fulfills these needs and further provides 
other related advantages. The animal toxicity bioassay data 
indicated that LD50 dose for all of the compounds are in the 
range of 250-3000 mg/kg, which is much lower compare to 
some of the most promising agents against breast cancer. For 
Breast cancer is a significant health problem for women in 
the United States and throughout the world. Although 
advances have been made in detection and treatment of the 
disease, breast cancer remains the second leading cause of 
cancer-related deaths in women, affecting more than 180, 
000 women in the United States each year. For women in 
North America, the life-time odds of getting breast cancer 
are now one in eight. 
15 example taxol intra-peritoneal LD50 dose in mice using the 
same bioassay system is 218 mg/kg (JZKEDZ 6,1,1980), 
which is almost a number of magnitude higher then some of 
the claimed compounds. Such a low toxicity dose of the 
compounds claimed gives a strong potential for not to 
20 having such a serious side effects as the most potential drugs 
of the present time do. Secondly, more advantages from our 
invention are the cheapness and the simplicity of the syn-
thesis of active compounds compare to the present drugs on 
the market. The synthesis of claimed compounds from No vaccine or other universally successful method for the prevention or treatment of breast cancer is currently avail-
able. The available drugs on the market have a variety of 
strong side effects, high cost and complicated synthesis. For 
example, Taxol is the most promising antitumor agent 
developed in the past three decades. It was approved by the 
FDA for the treatment of refractory ovarian cancer in 30 
December, 1992, and was introduced into the marketplace in 
January, 1993 by Bristol-Myers Squibb Company (EMS) 
operating under a Cooperative Research and Development 
Agreement (CRADA) with the National Cancer Institute 
(NCI). It was approved for the treatment of breast cancer in 35 
1994, and is now in transition from second line to first line 
therapy. Worldwide sales of Taxol reached $1.2 billion in 
1998. However, Preclinical development continued from 
1977 until 1983, hampered by a number of obstacles, 
especially the formulation problem. Taxol is highly lipo- 40 
philic and is insoluble in water. Finally, a vehicle consisting 
25 commercially available reagents takes four to five synthetic 
steps with overall yield in the range of 60--85%. Versus for 
example taxol which takes minimum of 40 synthetic steps 
with only 2% overall yield, which increases the price of the 
of a mixture of Cremophore EL (polyethoxylated caster oil), 
ethanol and saline was chosen, but its toxicity was a sig-
nificant problem in preclinical studies. The main side effects 
of this drug were found to be congenital malformation in the 45 
fetus and reproductive disorders. The supply of Taxol was 
also a problem. To obtain Yew bark, the tree had to be killed. 
A large Pacific Yew two feet in diameter requires 200 years 
to grow and yields about five pounds of bark. In extractions 
by Polysciences, then the only extraction contractor, a 50 
0.004% yield of Taxol was obtained. Furthermore, the 
Pacific Yew was a scarce understory tree, and its extinction 
and destruction of the old growth forests was threatened by 
the harvest. Few believed, because of the complexity of the 
molecule, that the problem of a commercial supply of Taxol 55 
could be solved by total synthesis. The first total synthesis 
was finally reported in 1994 by the Holton group. Although 
three total syntheses have been subsequently achieved by 
others, the Holton synthesis is the most efficient, but still 
requires over 40 steps from camphor and provides an overall 
yield of approximately 2%. 
compound dramatically. 
Conclusion: Although the invented compounds have not 
yet been tested clinically, one can see from the Table 1 that 
all of them posses at least 10 times lower acute toxicity 
compare to the most promising antitumor agent developed in 
the past three decades, high activity values, ease of 
synthesis, and cheap cost. All these advantages provide a 
potential for the development of new drugs for the preven-
tion or treatment of breast cancer. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope 
of the invention is not intended to be, nor should it be 
deemed to be, limited thereby and such other modifications 
or embodiments as may be suggested by the teachings herein 
are particularly reserved especially as they fall within the 
breadth and scope of the claims here appended. 
We claim: 
1. A compound consisting of 2-(N'-Fluoren-9-ylidene-
hydrazino )-5,5-dimethyl-4-oxo-hex-2-enoic acid methyl 
ester. 
2. A compound consisting of 2-Hydroxy-4-oxo-4-(2,3,5, 
6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid. 
3. A method of treating breast carcinoma in a human in 
need of such treatment comprising the steps of administering 
to said human, in a systemic, in vitro manner, an anti-tumor 
effective amount of a compound of claim 1 or claim 2 having 
the common property of anti-tumor activity against human 
breast cancer. 
* * * * * 
